Evolent Health (EVH) Tops Q4 EPS by 6c; offers guidance
Evolent Health (NYSE: EVH) reported Q4 EPS of $0.23, $0.06 better than the analyst estimate of $0.17. Revenue for the quarter came in at $556.06 million versus the consensus estimate of $542.45 million.
GUIDANCE:
Evolent Health sees Q1 2024 revenue of $595-610 million, versus the consensus of $551 million.
Evolent Health sees FY2024 revenue of $2.4-2.5 billion, versus the consensus of $2.324 billion.
For earnings history and earnings-related data on Evolent Health (EVH) click here.
